Search clinical trials for: AZD3161

Total 119 results

AstraZeneca

Completed

PET Study in Parkinson's Disease Patients

Parkinson's Disease

Sweden
AstraZeneca
Parexel

Recruiting

A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers

Healthy Volunteers

United States, Germany
AstraZeneca

Terminated

A Single and Multiple Ascending Dose Study With AZD9164 Given for 13 Days in Healthy Male and Female Japanese Subjects (JSMAD)

Healthy

United Kingdom
AstraZeneca

Withdrawn

Assessment of the Safety and Pharmacokinetics of Single and Multiple Oral Doses of AZD4316 in Healthy Subjects

Healthy Volunteers

United Kingdom
AstraZeneca

Completed

Investigating Safety, Tolerability and Pharmakinetics When Giving Single and Fractionated Doses of AZD3241 to Healthy Volunteers (SAD)

Healthy Volunteers

Sweden
Cancer Research UK
AstraZeneca

Completed

A Phase I Trial of AZD3965 in Patients With Advanced Cancer

Adult Solid Tumor | Burkitt Lymphoma | Diffuse Large B Cell Lymphoma

United Kingdom
AstraZeneca

Completed

A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease

Parkinson's Disease

United States
AstraZeneca

Completed

AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients

Multiple System Atrophy, MSA

United States, Finland, Austria, France, Sweden, United Kingdom, Italy
AstraZeneca

Active, not recruiting

Study of AZD3152 Intramuscular Injection or Intravenous Infusion in Healthy Japanese Adult Participants

COVID-19, SARS-CoV-2

Japan
AstraZeneca

Active, not recruiting

Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response Study

COVID-19

United States
AstraZeneca

Completed

Study to Evaluate Different Extended Release (ER)-Formulations and Multiple Ascending Dosing of AZD3241

Healthy

Sweden
AstraZeneca

Active, not recruiting

Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19 (NOVELLA)

COVID-19, SARS-CoV-2

Russian Federation
AstraZeneca

Terminated

Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects

Thrombin Inhibition

United States
AstraZeneca

Terminated

A Multiple Ascending Dose Study With AZD9164 Given for 13 Days in Healthy Male and Female Subjects and in Patients With Chronic Obstructive Pulmonary Disease

Healthy | COPD

Sweden
AstraZeneca

Completed

Determine the Effect of AZD3161,Injected Intradermally, on Quantitative Sensory Testing Variables in Normal and Ultraviolet-C (UVC) Exposed Skin in Healthy Volunteers

Nociceptive Pain | Peripheral Neuropathic Pain

United Kingdom
AstraZeneca

Completed

AZD9164 Single Ascending Dose Study in Healthy Male Subjects

Healthy

Sweden
AstraZeneca

Completed

An Open-Label, Dose-Escalation Study of AZD2461

Refractory Solid Tumors | Cancer Tumor

United States
The Christie NHS Foundation Trust
AstraZeneca; Cancer Research UK

Terminated

Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial (DREAMtherapy)

Rectal Cancer

United Kingdom
National Cancer Institute (NCI)

Completed

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors

Recurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Childhood Atypical Teratoid/Rhabdoid Tumor | Childhood Grade I Meningioma | Childhood Grade II Meningioma | Childhood Grade III Meningioma | Childhood Infratentorial Ependymoma | Childhood Supratentorial Ependymoma | Recurrent Childhood... and other conditions

United States
National Cancer Institute (NCI)

Terminated

AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine

Neurofibromatosis Type 1 | Plexiform Neurofibroma | Spinal Cord Neurofibroma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma

United States
National Cancer Institute (NCI)

Completed

Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer

Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Salivary Gland Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Nasopharyngeal Keratinizing Squamous... and other conditions

United States
AstraZeneca

Completed

Evaluation of the Pharmacokinetics and the Pharmacodynamics of Different Dry Powder Inhalation Formulations of AZD3199 in Patients With Asthma

Asthma

Sweden
AstraZeneca
Iqvia Pty Ltd

Active, not recruiting

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. (PROVENT)

COVID-19

United States, Belgium, France, Spain, United Kingdom
AstraZeneca

Completed

To Assess the Effect of Administration of 2 Formulation of AZD3241 on Blood Concentration in Healthy Volunteers

Parkinson's Disease

United Kingdom
AstraZeneca

Completed

Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants

Corona Virus Disease

United States
National Cancer Institute (NCI)

Completed

Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain Neoplasm

United States
AstraZeneca

Active, not recruiting

Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study (SUPERNOVA)

COVID-19, SARS-CoV-2

United States, Belgium, Canada, France, Spain, Denmark, Thailand, Vietnam, Korea, Republic of, United Kingdom, Malaysia, Israel, Taiwan, Australia, Germany, Poland, Singapore, United Arab Emirates
Peter MacCallum Cancer Centre, Australia

Recruiting

Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer (LuCAB)

Metastatic Castration-resistant Prostate Cancer | mCRPC

Australia
National Cancer Institute (NCI)

Completed

Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery

Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer

Canada
Medical Research Council
National Health and Medical Research Council, Australia; AstraZeneca; Cancer... and other collaborators

Unknown

An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer (ICON6)

Ovarian Cancer

United Kingdom
AstraZeneca

Completed

Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours

Hepatic Impairment | Advanced Cancer

Netherlands, Denmark
AstraZeneca

Completed

Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer (AZD2171IL/0003)

Advanced Prostate Adenocarcinoma

United States
AstraZeneca

Completed

Phase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AML

Acute | Leukaemia | Myelocytic
National Cancer Institute (NCI)

Active, not recruiting

Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma

Sarcoma, Alveolar Soft Part

United States
National Cancer Institute (NCI)

Completed

AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

Fallopian Tube Cancer | Primary Peritoneal Serous Adenocarcinoma | Recurrent Ovarian Epithelial Cancer | Stage I Ovarian Epithelial Cancer | Stage II Ovarian Epithelial Cancer

United States
National Cancer Institute (NCI)

Completed

Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma | Localized Malignant Mesothelioma

United States
National Cancer Institute (NCI)

Completed

AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain Tumor

United States
AstraZeneca

Completed

Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver Metastases

Advanced Solid Tumor | Liver Metastases

Germany
AstraZeneca

Terminated

A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19 (ENDURE)

Coronavirus Disease 2019 (COVID-19)

United States
National Cancer Institute (NCI)

Completed

AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma

Intraocular Melanoma | Recurrent Melanoma | Stage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Extraocular Extension Melanoma | Acral Lentiginous Malignant Melanoma | Lentigo Maligna Malignant Melanoma | Superficial... and other conditions

Canada
AstraZeneca

Completed

Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tumours

Tumors

Netherlands, Germany, United Kingdom
AstraZeneca

Completed

The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer

Carcinoma | Head and Neck Neoplasms | Non-Small-Cell Lung Carcinoma

United States, Spain
AstraZeneca

Completed

A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

China
AstraZeneca

Completed

A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan

Advanced Solid Tumor

Japan
AstraZeneca

Completed

Phase I Orally Administered 14C-AZD2171 in Patients With Solid Metastatic Tumors

Advanced Solid Metastatic Tumor

United Kingdom
National Cancer Institute (NCI)

Completed

AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
AstraZeneca

Completed

Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid Tumours

Advanced Solid Tumors

Denmark, Canada
AstraZeneca

Completed

Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer

Advanced Tumor

Netherlands
AstraZeneca

Completed

Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma

Renal Cell Carcinoma

United Kingdom, Netherlands

Search clinical trials for: AZD3161

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations